Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases / 대한내과학회지
Korean Journal of Medicine
;
: 446-451, 2013.
Article
in Korean
| WPRIM
| ID: wpr-117705
ABSTRACT
Sarcomatoid carcinoma of the lung is defined as a group of poorly differentiated non-small cell carcinomas that contain a component of sarcoma or a sarcoma-like element. Most sarcomatoid carcinomas are known to have a poor prognosis. We describe a 45-year-old female never smoker and 49-year-old female never smoker with sarcomatoid carcinomas of the lung that expressed a specific EGFR mutation microdeletion of exon 19. Their cancers progressed rapidly, despite appropriate conventional chemotherapy. After they took the EGFR-targeted agent gefitinib, there was a dramatic reduction in tumor size. Sarcomatoid carcinoma of the lung is a rare cancer whose pathogenesis is not well understood. According to these cases, the EGFR mutation could be a driver mutation and the potential therapeutic target of EGFR-targeted agents for sarcomatoid carcinoma in lung cancer patients, especially never smokers.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Quinazolines
/
Sarcoma
/
Exons
/
Genes, erbB-1
/
Lung
/
Lung Neoplasms
Type of study:
Prognostic study
Limits:
Female
/
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS